Whole-Body Vibration on Balance, Risk of Falling and Quality of Life in Chemotherapy-Induced Peripheral Neuropathy

NCT07508527 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-02

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy of Whole-body vibration in improving postural control, risk of falling, and quality of life in patients with chemotherapy-induced peripheral neuropathy. The main questions it aims to answer are:

Does Whole-body vibration have a significant effect on postural control, risk of falling, and quality of life in patients with chemotherapy-induced peripheral neuropathy?

Researchers will compare whole body vibration in addition to traditional exercise to traditional exercise alone to see if Whole-body vibration have a significant effect on postural control, risk of falling, and quality of life in patients with chemotherapy-induced peripheral neuropathy.

Participants will:

* age between 30-60 years old.
* be on chemotherapy for at least one cycle as a treatment of malignant tumors with peripheral neuropathy.
* have mild to moderate neuropathy according to mTNS.
* be assigned randomly into two equal groups (control group (A) and study group (B)).
* Take three sessions per week for eight weeks.
* The control group (A) will be treated by selected physical therapy treatment (Strength resistive training, Stretching \& flexibility, Balance training)
* The study group (B) will be treated with selected physical therapy treatment in addition to whole-body vibration therapy.

Conditions

  • Whole Body Vibration
  • Chemotherapy Induced Peripheral Neuropathy (CIPN)
  • Fall Risk, Fall Prevention
  • Balance
  • Quality of Life

Interventions

DEVICE

Whole Body Vibration

15 min of Whole-body vibration therapy 3 sessions per week for 8 weeks, as follow: 24 * Duration: about 15 minutes per session * Vibration Frequency: 18-40 Hz (starting at lower frequency and progressing) * Position: Standing on the platform with slight knee flexion to activate muscles, progressing to squats and dynamic movements over time. The patient may start standing. * Progression Plan: * Weeks 1-2: Low frequency (18-25 Hz) for short intervals * Weeks 3-5: Increase frequency to (25-35 Hz) with longer intervals * Weeks 6-8: Progress to higher frequency (35-40 Hz) with the introduction of additional balance exercises while on the platform (e.g., squats, heel raises).

OTHER

Traditional exercise

-Strength resistive training: Core strengthening, Squat \& set up, sit to stand exercise, calf raises \& squats, Seated leg ex, Straight leg raising exercise, clamshell, Dorsi flexion exercise, Quad set -Stretching \& flexibility: Stretch for lower limb (Hamstring, Calf) \- Balance training: Single leg stance (Stable surface then unstable one), Gait training with obstacles \& alternating speed \& different directions (side steps, steps over cones), Balane board.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Bothina Sayed Mohamed, Bachelor's Degree · Physical Therapist at Department of clinical oncology and nuclear medicine, Cairo university Hospitals (Kasr El-Einy); Bachelor's Degree from Faculty of Physical Therapy, Cairo University

  • Mohamed Abd El-Rahman Hassan, Professor of Clinical Oncology · Professor of Clinical Oncology, Department of clinical oncology and nuclear medicine, Faculty of Medicine, Kasr El-Einy, Cairo University.

  • Nahed Ahmed Salem, Professor of Physical Therapy · Professor of Physical Therapy for Neurology and Neurosurgery, Faculty of Physical Therapy, Cairo University

  • Mohamed Helayel Marzouk, Lecture of Physical Therapy · Lecture of Physical Therapy for Neurology and Neurosurgery, Faculty of Physical Therapy, Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2027-04-30
Completion
2027-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07508527 on ClinicalTrials.gov